Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07293351) titled 'A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Advanced Renal Cell Carcinoma (RCC)
Intervention:
Drug: Pumitamig
Drug: Ipilimumab
Drug: Cabozantinib
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enroll...